Show simple item record

Files in this item


Item metadata

dc.contributor.authorTorabi, Fatemeh
dc.contributor.authorBedston, Stuart
dc.contributor.authorLowthian, Emily
dc.contributor.authorAkbari, Ashley
dc.contributor.authorOwen, Rhiannon K
dc.contributor.authorBradley, Declan
dc.contributor.authorAgrawal, Utkarsh
dc.contributor.authorCollins, Peter
dc.contributor.authorFry, Richard
dc.contributor.authorGriffiths, Lucy J
dc.contributor.authorBeggs, Jillian
dc.contributor.authorDavies, Gareth
dc.contributor.authorHollinghurst, Joe
dc.contributor.authorLyons, Jane
dc.contributor.authorAbbasizanjani, Hoda
dc.contributor.authorCottrell, Simon
dc.contributor.authorPerry, Malorie
dc.contributor.authorRoberts, Richard
dc.contributor.authorAzcoaga-Lorenzo, Amaya
dc.contributor.authorFagbamigbe, Adeniyi
dc.contributor.authorShi, Ting
dc.contributor.authorTang, Ruby S. M.
dc.contributor.authorRobertson, Chris
dc.contributor.authorHobbs, Richard
dc.contributor.authorde Lusignan, Simon
dc.contributor.authorMcCowan, Colin
dc.contributor.authorGravenor, Michael
dc.contributor.authorSimpson, Colin
dc.contributor.authorSheikh, Aziz
dc.contributor.authorLyons, Ronan A.
dc.identifier.citationTorabi , F , Bedston , S , Lowthian , E , Akbari , A , Owen , R K , Bradley , D , Agrawal , U , Collins , P , Fry , R , Griffiths , L J , Beggs , J , Davies , G , Hollinghurst , J , Lyons , J , Abbasizanjani , H , Cottrell , S , Perry , M , Roberts , R , Azcoaga-Lorenzo , A , Fagbamigbe , A , Shi , T , Tang , R S M , Robertson , C , Hobbs , R , de Lusignan , S , McCowan , C , Gravenor , M , Simpson , C , Sheikh , A & Lyons , R A 2022 , ' Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test : a self-controlled case series analysis in Wales ' , Scientific Reports , vol. 12 , 16406 .
dc.identifier.otherORCID: /0000-0002-9466-833X/work/120432859
dc.identifier.otherORCID: /0000-0003-3307-878X/work/120434356
dc.descriptionFunding: This work was supported by the Medical Research Council [MR/V028367/1]; Health Data Research UK [HDR-9006] which receives its funding from the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust; and Administrative Data Research UK which is funded by the Economic and Social Research Council [grant ES/S007393/1]. This work was supported by the Wales COVID-19 Evidence Centre, funded by Health and Care Research Wales. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation. We also acknowledge the support of the HDR UK BREATHE Hub, funded by the Industrial Strategy Challenge Fund through a grant via Health Data Research UK.en
dc.description.abstractThere is a need for better understanding of the risk of thrombocytopenic, haemorrhagic, thromboembolic disorders following first, second and booster vaccination doses and testing positive for SARS-CoV-2. Self-controlled cases series analysis of 2.1 million linked patient records in Wales between 7th December 2020 and 31st December 2021. Outcomes were the first diagnosis of thrombocytopenic, haemorrhagic and thromboembolic events in primary or secondary care datasets, exposure was defined as 0–28 days post-vaccination or a positive reverse transcription polymerase chain reaction test for SARS-CoV-2. 36,136 individuals experienced either a thrombocytopenic, haemorrhagic or thromboembolic event during the study period. Relative to baseline, our observations show greater risk of outcomes in the periods post-first dose of BNT162b2 for haemorrhagic (IRR 1.47, 95%CI: 1.04–2.08) and idiopathic thrombocytopenic purpura (IRR 2.80, 95%CI: 1.21–6.49) events; post-second dose of ChAdOx1 for arterial thrombosis (IRR 1.14, 95%CI: 1.01–1.29); post-booster greater risk of venous thromboembolic (VTE) (IRR-Moderna 3.62, 95%CI: 0.99–13.17) (IRR-BNT162b2 1.39, 95%CI: 1.04–1.87) and arterial thrombosis (IRR-Moderna 3.14, 95%CI: 1.14–8.64) (IRR-BNT162b2 1.34, 95%CI: 1.15–1.58). Similarly, post SARS-CoV-2 infection the risk was increased for haemorrhagic (IRR 1.49, 95%CI: 1.15–1.92), VTE (IRR 5.63, 95%CI: 4.91, 6.4), arterial thrombosis (IRR 2.46, 95%CI: 2.22–2.71). We found that there was a measurable risk of thrombocytopenic, haemorrhagic, thromboembolic events after COVID-19 vaccination and infection. 
dc.relation.ispartofScientific Reportsen
dc.subjectCOVID-19 vaccinesen
dc.subjectSARS-CoV-2 infectionen
dc.subjectAdverse thrombosis eventsen
dc.subjectElectronic health recordsen
dc.subjectPopulation studyen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleRisk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test : a self-controlled case series analysis in Walesen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Population and Behavioural Science Divisionen
dc.contributor.institutionUniversity of St Andrews. Sir James Mackenzie Institute for Early Diagnosisen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record